首页> 外文OA文献 >Superior Anti-tumor Efficacy of Bicalutamide 80 mg in Combination with a Luteinizing Hormone-releasing Hormone (LHRH) Agonist Versus LHRH Agonist Monotherapy as First-line Treatment for Advanced Prostate Cancer: Interim Results of a Randomized Study in Japanese Patients

【2h】

Superior Anti-tumor Efficacy of Bicalutamide 80 mg in Combination with a Luteinizing Hormone-releasing Hormone (LHRH) Agonist Versus LHRH Agonist Monotherapy as First-line Treatment for Advanced Prostate Cancer: Interim Results of a Randomized Study in Japanese Patients

机译：与丁黄激素释放激素（LHRH）激动剂（LHRH）激动剂与LHRH激动剂单疗作用相结合的优异的抗肿瘤效果与LHRH激动剂单疗法为一线治疗前列腺癌：日本患者随机研究的中期结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
H. Akaza;
展开▼
作者单位

展开▼
年度 2004
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Superior Anti-tumor Efficacy of Bicalutamide 80 mg in Combination with a Luteinizing Hormone-releasing Hormone (LHRH) Agonist Versus LHRH Agonist Monotherapy as First-line Treatment for Advanced Prostate Cancer: Interim Results of a Randomized Study [J] . Akaza H, Matsuda T, Kumon H, Japanese journal of clinical oncology. . 2004,第1期

机译：比卡鲁胺80毫克与黄体激素释放激素（LHRH）激动剂与LHRH激动剂单一疗法联合治疗晚期前列腺癌的一线治疗具有卓越的抗肿瘤功效：一项随机研究的中期结果
2. Bicalutamide 80|[thinsp]|mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients [J] . M Usami, H Akaza, Y Arai, Prostate Cancer and Prostatic Diseases . 2007,第2期

机译：比卡鲁胺80 | [thin] | mg与促黄体激素释放激素激动剂（LHRH-A）对比LHRH-A单药治疗晚期前列腺癌：来自日本患者的一项III期随机，双盲，多中心试验的结果
3. Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials [J] . Peter Iversen, Jan-Erik Damber, Anders Malmberg, Therapeutic advances in urology. . 2016,第2期

机译：Degarelix单一疗法与促黄体激素释放激素（LHRH）激动剂加抗雄激素耀斑保护在晚期前列腺癌中的比较：两项随机对照试验的分析
4. Changes in bone mineral density in men with prostate cancer during treatment with luteinizing hormone-releasing hormone (LHRH) agonist monotherapy. [D] . Conde, Francisco Alcasid, II. 2003

机译：黄体激素释放激素（LHRH）激动剂单药治疗期间前列腺癌男性的骨矿物质密度变化。
5. Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials [O] . Peter Iversen, Jan-Erik Damber, Anders Malmberg, 2016

机译：Degarelix单一疗法与促黄体激素释放激素（LHRH）激动剂加抗雄激素耀斑保护在晚期前列腺癌中的比较：两项随机对照试验的分析
6. Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer : an analysis of two randomized controlled trials [O] . Iversen, Peter, Damber, Jan-Erik, Malmberg, Anders, 2016

机译：Degarelix单一疗法与促黄体激素释放激素（LHRH）激动剂加抗雄激素耀斑保护在晚期前列腺癌中的比较：两项随机对照试验的分析

Superior Anti-tumor Efficacy of Bicalutamide 80 mg in Combination with a Luteinizing Hormone-releasing Hormone (LHRH) Agonist Versus LHRH Agonist Monotherapy as First-line Treatment for Advanced Prostate Cancer: Interim Results of a Randomized Study in Japanese Patients

著录项

引文网络

相似文献

相关主题

期刊订阅